Ascend Gene & Cell Therapies

Founded in 2021, Ascend is building a new model of CDMO (contract development and manufacturing outsourcing) to tackle the growing disconnect between supply and demand in gene therapy production and enable these lifechanging therapies to reach their fullest potential. Headquartered in the UK, the company combines an upstream R&D innovation function in San Francisco, a process development and analytics division in Munich, and a GMP production site in London to offer end-to-end support to gene therapy developers from design through to clinical and commercial scale manufacturing.